Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Arch Virol. 2022 Mar;167(3):751-805. doi: 10.1007/s00705-022-05368-z. Epub 2022 Feb 9.
In the current pandemic of coronavirus disease 2019 (COVID-19), antiviral drugs are at the center of attention because of their critical role against severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2). In addition to designing new antivirals against SARS-COV-2, a drug repurposing strategy is a practical approach for treating COVID-19. A brief insight about antivirals would help clinicians to choose the best medication for the treatment of COVID-19. In this review, we discuss both novel and repurposed investigational antivirals, focusing on in vitro, in vivo, and clinical trial studies.
在当前的 2019 冠状病毒病(COVID-19)大流行中,抗病毒药物因其对抗严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的关键作用而成为关注焦点。除了设计针对 SARS-CoV-2 的新型抗病毒药物外,药物再利用策略是治疗 COVID-19 的一种实用方法。对抗病毒药物的简要了解将有助于临床医生选择治疗 COVID-19 的最佳药物。在这篇综述中,我们讨论了新型和再利用的研究性抗病毒药物,重点介绍了体外、体内和临床试验研究。